keyword
https://read.qxmd.com/read/38232722/variations-in-patterns-of-prescribing-durvalumab-in-stage-iii-lung-cancer-a-survey-of-australian-medical-oncologists
#21
Udit Nindra, Victoria Bray, Deme Karikios, Mohsen Shafiei, Shalini Subramaniam, Pei Ding, Steven Kao, Abhijit Pal
BACKGROUND: Local Australian guidelines for the optimal management of stage III unresectable NSCLC are lacking. The American Society of Clinical Oncology (ASCO) guidelines recommend consolidation durvalumab for all patients with unresectable stage III NSCLC irrespective of their PD-L1 expression or driver mutation status. The European Society of Medical Oncology (ESMO) differs, with consolidation durvalumab only recommended in those patients whose tumours express PD-L1. METHODS: Due to differing global guidelines we conducted an Australia and New Zealand wide survey of medical oncologists specialising in thoracic cancer to determine the variations in patterns of prescribing durvalumab in stage III unresectable NSCLC...
January 17, 2024: Oncology
https://read.qxmd.com/read/38196524/a-narrative-review-of-the-evolving-landscape-of-the-management-of-metastatic-gastric-cancer-the-role-of-targeted-therapies
#22
REVIEW
Glenda M Delgado-Ramos, Jack Fitzsimons, Asha Dhanarajan
BACKGROUND AND OBJECTIVE: Gastric cancer is the fifth most common cancer worldwide and the fourth leading cause of cancer-related death. Unfortunately, patients often present with advanced disease at diagnosis, which is directly related to its high mortality. Numerous trials, as early as the 1980's, have shown that cytotoxic chemotherapy improves survival. This review will focus on targeted therapies and immunotherapies which have emerged as treatment options for metastatic gastric cancer, often used in conjunction with cytotoxic chemotherapy...
December 31, 2023: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38177714/acetone-compression-improves-lymph-node-yield-and-metastasis-detection-in-colorectal-cancer
#23
JOURNAL ARTICLE
Christina Schnoz, Katrin Schmid, Guacimara Ortega Sanchez, Sabina Schacher-Kaufmann, Michel Adamina, Georgios Peros, Dieter Erdin, Peter Karl Bode
Lymph node status is one of the most important prognostic factors in colorectal cancer, and accurate pathological nodal staging and detection of lymph node metastases is crucial for determination of post-operative management. Current guidelines, including the TNM staging system and European Society for Medical Oncology (ESMO) guidelines, recommend examination of at least 12 lymph nodes. However, identification of an adequate number of lymph nodes can be challenging, especially in the setting of neoadjuvant treatment, which may reduce nodal size...
January 4, 2024: Clinical & Experimental Metastasis
https://read.qxmd.com/read/38175594/frequency-and-prognostic-value-of-circulating-tumor-cells-in-cancer-of-unknown-primary
#24
JOURNAL ARTICLE
Maria Pouyiourou, Tilmann Bochtler, Cornelia Coith, Harriet Wikman, Bianca Kraft, Thomas Hielscher, Albrecht Stenzinger, Sabine Riethdorf, Klaus Pantel, Alwin Krämer
BACKGROUND: Cancer of unknown primary (CUP) is defined as a primary metastatic malignancy, in which the primary tumor remains elusive in spite of a comprehensive diagnostic workup. The frequency and prognostic value of circulating tumor cells (CTCs), which are considered to be the source of metastasis, has not yet been systematically evaluated in CUP. METHODS: A total of 110 patients with a confirmed diagnosis of CUP according to the European Society for Medical Oncology (ESMO) guidelines, who presented to our clinic between July 2021 and May 2023, provided blood samples for CTC quantification using CellSearch methodology...
January 4, 2024: Clinical Chemistry
https://read.qxmd.com/read/38171975/early-recognition-and-management-of-side-effects-related-to-systemic-anticancer-therapy-for-advanced-breast-cancer
#25
JOURNAL ARTICLE
Celia Diez de Los Rios de la Serna, Christine Bettine Boers-Doets, Theresa Wiseman, Bhaveet Radia, Ruth Hammond
OBJECTIVES: Advances in science and technology have meant there are numerous treatment options available for people with advanced breast cancer (ABC). However, each therapeutic approach can cause side effects or adverse events, which can significantly affect the person's quality of life, overall well-being, and, in some instances, safety. This report presents an overview of the common side effects of systemic anticancer therapy and ways to manage them. DATA SOURCES: Data sources include peer-reviewed articles sourced in electronic databases and national and international best practice guidelines (ESMO, ASCO, and MASCC guidelines)...
January 3, 2024: Seminars in Oncology Nursing
https://read.qxmd.com/read/38158225/insomnia-in-adult-patients-with-cancer-esmo-clinical-practice-guideline
#26
L Grassi, R Zachariae, R Caruso, L Palagini, R Campos-Ródenas, M B Riba, M Lloyd-Williams, D Kissane, G Rodin, D McFarland, C I Ripamonti, D Santini
• Insomnia is common in patients with cancer, with a higher prevalence than observed in the general population. • Insomnia is often under-recognised and inadequately treated in patients with cancer. • Brief validated screening tools are available for the evaluation of insomnia in clinical practice. • First-line therapy should be based on international guidelines recommending cognitive behavioural therapy for insomnia.
December 2023: ESMO Open
https://read.qxmd.com/read/38141097/the-role-of-total-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-a-survey-of-specialists-attending-the-all-ireland-colorectal-cancer-conference-2022-including-lead-investigators-of-opra-prodige-23-and-rapido
#27
JOURNAL ARTICLE
Timothy O'Brien, Geke Hospers, Thierry Conroy, Heinz-Josef Lenz, Jesse Joshua Smith, Emmet Andrews, Brian O'Neill, Gregory Leonard
BACKGROUND: The treatment of locally advanced rectal cancer (LARC) has evolved following recent landmark trials of total neoadjuvant therapy (TNT)-the delivery of preoperative chemotherapy sequenced with radiation. AIM: To assess the preferences of colorectal surgery (CRS), radiation oncology (RO) and medical oncology (MO) specialists attending the All-Ireland Colorectal Cancer Conference (AICCC) 2022 regarding the neoadjuvant management of LARC. METHODS: A live electronic survey explored the preferred treatment approach and TNT regimen for early-, intermediate-, bad-, and advanced-risk categories of rectal cancer according to the European Society of Medical Oncology (ESMO) guidelines...
December 23, 2023: Irish Journal of Medical Science
https://read.qxmd.com/read/38135822/mascc-esmo-antiemetic-guidelines-introduction-to-the-2023-guidelines-update
#28
EDITORIAL
J Herrstedt, R Clark-Snow, C H Ruhlmann, K Jordan, F Scotté
No abstract text is available yet for this article.
December 22, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38129530/emetic-risk-classification-and-evaluation-of-the-emetogenicity-of-antineoplastic-agents-updated-mascc-esmo-consensus-recommendation
#29
JOURNAL ARTICLE
Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport, Christina H Ruhlmann, Paula Sayegh, Paul J Hesketh
PURPOSE: Our goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) since the 2016 MASCC/ESMO antiemetic update and classify their emetic potential. METHODS: The MASCC/ESMO Expert Panel classified the emetogenicity of the identified new antineoplastic agents based on nonsystematic reviews of randomized controlled trials, analysis of product labeling, and evaluation of emetic classification in other international guidelines and informal consensus...
December 22, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38127246/2023-updated-mascc-esmo-consensus-recommendations-prevention-of-nausea-and-vomiting-following-high-emetic-risk-antineoplastic-agents
#30
JOURNAL ARTICLE
Jørn Herrstedt, L Celio, P J Hesketh, L Zhang, R Navari, A Chan, M Saito, R Chow, M Aapro
PURPOSE: This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016-2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500 mg/m2 and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer. METHODS: A systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed...
December 21, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38114821/2023-updated-mascc-esmo-consensus-recommendations-prevention-of-nausea-and-vomiting-following-moderately-emetic-risk-antineoplastic-agents
#31
JOURNAL ARTICLE
Florian Scotté, Lee Schwartzberg, Hirotoshi Lihara, Matti Aapro, Richard Gralla, Paul J Hesketh, Karin Jordan, Ronald Chow, Jørn Herrstedt
PURPOSE: Review the literature to update the MASCC guidelines from 2015 for controlling nausea and vomiting with systemic cancer treatment of moderate emetic potential. METHODS: A systematic literature review was completed using Medline, Embase, and Scopus databases. The literature search was done from June 2015 to January 2023 of the management of antiemetic prophylaxis for anticancer therapy of moderate emetic potential. RESULTS: Of 342 papers identified, 19 were relevant to update recommendations about managing antiemetic prophylaxis for systemic cancer treatment regimens of moderate emetic potential...
December 20, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38110581/2023-updated-mascc-esmo-consensus-recommendations-controlling-nausea-and-vomiting-with-chemotherapy-of-low-or-minimal-emetic-potential
#32
JOURNAL ARTICLE
Ian Olver, Rebecca Clark-Snow, Christina H Ruhlmann, Maria-Angeles Garcia-Del-Barrio, Lee Schwartzberg, Bernardo Leon Rapoport, Franziska Jahn
PURPOSE: Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential. METHODS: A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%...
December 19, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38102373/2023-mascc-esmo-consensus-antiemetic-guidelines-related-to-integrative-and-non-pharmacological-therapies
#33
JOURNAL ARTICLE
A Molassiotis, Mary Lou Affronti, Mapi Fleury, Ian Olver, Raffaele Giusti, Florian Scotte
PURPOSE: Review the literature to propose suggestions or recommendations for controlling nausea and vomiting through integrative and non-pharmacological treatments for the MASCC/ESMO 2023 update of its antiemetic guidelines. METHODS: The authors identified available systematic reviews and/or meta-analyses for 12 integrative therapies, including acupressure, acupuncture, auricular therapy, electrical stimulation of point PC6, ginger use (i.e., Zingiber officinale), guided imagery, hypnosis, inhalation aromatherapy, music therapy, food-based interventions, progressive muscle relaxation, and reflexology...
December 16, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38101773/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and-follow-up-%C3%A2
#34
S Loibl, F André, T Bachelot, C H Barrios, J Bergh, H J Burstein, L M J Cardoso, L A Carey, S Dawood, L Del Mastro, C Denkert, E M Fallenberg, P A Francis, H Gamal-Eldin, K Gelmon, C E Geyer, M Gnant, V Guarneri, S Gupta, S B Kim, D Krug, M Martin, I Meattini, M Morrow, W Janni, S Paluch-Shimon, A Partridge, P Poortmans, L Pusztai, M M Regan, J Sparano, T Spanic, S Swain, S Tjulandin, M Toi, D Trapani, A Tutt, B Xu, G Curigliano, N Harbeck
No abstract text is available yet for this article.
December 8, 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38100933/discontinuation-rate-and-serious-adverse-events-of-chemoimmunotherapy-as-neoadjuvant-treatment-for-triple-negative-breast-cancer-a-systematic-review-and-meta-analysis
#35
JOURNAL ARTICLE
A Rizzo, F M Schipilliti, F Di Costanzo, S Acquafredda, G Arpino, F Puglisi, L Del Mastro, F Montemurro, M De Laurentiis, M Giuliano
BACKGROUND: The use of combination of chemotherapy with immune checkpoint inhibitors (ICIs) has shown efficacy in triple-negative breast cancer (TNBC), and chemoimmunotherapy has been introduced in clinical practice. However, limited data are available on the discontinuation rate and serious adverse events of these treatments, particularly in the neoadjuvant setting. Herein, we carried out a comprehensive systematic review and meta-analysis to assess discontinuation rate and serious adverse events of chemoimmunotherapy compared to chemotherapy alone in phase II and III neoadjuvant clinical trials in TNBC...
December 2023: ESMO Open
https://read.qxmd.com/read/38097904/2023-updated-mascc-esmo-consensus-recommendations-prevention-of-radiotherapy-and-chemoradiotherapy-induced-nausea-and-vomiting
#36
REVIEW
Christina H Ruhlmann, Karin Jordan, Franziska Jahn, Ernesto Maranzano, Alex Molassiotis, Kristopher Dennis
PURPOSE: Radiotherapy and chemoradiotherapy-induced nausea and vomiting (RINV and C-RINV) are common and distressing, and there is a need for guidance for clinicians to provide up to date optimal antiemetic prophylaxis and treatment. Through a comprehensive review of the literature concerning RINV and C-RINV, this manuscript aims to update the evidence for antiemetic prophylaxis and rescue therapy and provide a new edition of recommendations for the MASCC/ESMO antiemetic guidelines for RINV and C-RINV...
December 15, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38070435/molecular-profiling-and-feasibility-using-a-comprehensive-hybrid-capture-panel-on-a-consecutive-series-of-non-small-cell-lung-cancer-patients-from-a-single-centre
#37
JOURNAL ARTICLE
M Mosteiro, D Azuara, S Villatoro, A Alay, M Gausachs, M Varela, N Baixeras, L Pijuan, M Ajenjo-Bauza, A Lopez-Doriga, Á Teulé, A Solanes, R Palmero, J Brenes, M Jové, S Padrones, V Moreno, D Cordero, X Matías-Guiu, C Lázaro, E Nadal
BACKGROUND: Targeted next-generation sequencing (NGS) is recommended to screen actionable genomic alterations (GAs) in patients with non-small-cell lung cancer (NSCLC). We determined the feasibility to detect actionable GAs using TruSight™ Oncology 500 (TSO500) in 200 consecutive patients with NSCLC. MATERIALS AND METHODS: DNA and RNA were sequenced on an Illumina® NextSeq 550 instrument and processed using the TSO500 Docker pipeline. Clinical actionability was defined within the molecular tumour board following European Society for Medical Oncology (ESMO) guidelines for oncogene-addicted NSCLC...
December 8, 2023: ESMO Open
https://read.qxmd.com/read/38067406/analysis-of-health-related-quality-of-life-reporting-in-phase-iii-rcts-of-advanced-genitourinary-tumors
#38
JOURNAL ARTICLE
Fabrizio Di Costanzo, Fabiana Napolitano, Fabio Salomone, Anna Rita Amato, Gennaro Alberico, Fortuna Migliaccio, Giovanna Pecoraro, Annachiara Marra, Felice Crocetto, Antonio Ruffo, Sarah Scagliarini, Sabrina Rossetti, Livio Puglia, Marilena Di Napoli, Roberto Bianco, Alberto Servetto, Luigi Formisano
BACKGROUND: As recommended in the European Society for Medical Oncology (ESMO) guidelines, assessment of health-related quality of life (HRQoL) should be a relevant endpoint in randomized controlled trials (RCTs) testing new anticancer therapies. However, previous publications by our group and others revealed a frequent underestimation and underreporting of HRQoL results in publication of RCTs in oncology. Herein, we systematically reviewed HRQoL reporting in RCTs testing new treatments in advanced prostate, kidney and urothelial cancers and published between 2010 and 2022...
December 4, 2023: Cancers
https://read.qxmd.com/read/38061978/epidemiology-management-and-survival-outcomes-of-germ-cell-cancer-in-southern-portugal-a-population-based-study-2008-2012
#39
JOURNAL ARTICLE
Margarida Brito, Marco Ramos, José Pais Silva, Gabriela Câmara, Alexandra Mayer, Ana Miranda, José Luís Passos Coelho, António Moreira, Susana Esteves
INTRODUCTION: Building on previous suboptimal survival results, we aimed to perform a study of the epidemiological status, management, and outcomes of germ cell tumors (GCT) in the Portuguese population. MATERIALS AND METHODS: Retrospective populational study of GCT cases diagnosed between 2008 and 2012 in southern Portugal. Joinpoint regression was used to compute average annual percentage change (AAPC) in incidence rate. ESMO/EAU guidelines served as references to evaluate compliance...
November 10, 2023: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38006283/impact-of-genetic-counselling-strategy-on-diagnostic-yield-and-workload-for-genome-sequencing-based-tumour-diagnostics
#40
JOURNAL ARTICLE
Roelof Koster, Luuk J Schipper, Noor A A Giesbertz, Daphne van Beek, Matías Mendeville, Kris G Samsom, Efraim H Rosenberg, Frans B L Hogervorst, Paul Roepman, Mirjam C Boelens, Linda J W Bosch, Jose G van den Berg, Gerrit A Meijer, Emile E Voest, Edwin Cuppen, Marielle W G Ruijs, Tom van Wezel, Lizet van der Kolk, Kim Monkhorst
PurposeGenome sequencing (GS) enables comprehensive molecular analysis of tumours and identification of hereditary cancer predisposition. According to guidelines, directly determining pathogenic germline variants (PGVs) requires pre-test genetic counselling, which is cost-ineffective. Referral for genetic counselling based on tumour variants alone could miss relevant PGVs and/or result in unnecessary referrals. MethodsWe validated GS for detection of germline variants and simulated three strategies using paired tumour-normal genome sequencing data of 937 metastatic patients...
November 22, 2023: Genetics in Medicine: Official Journal of the American College of Medical Genetics
keyword
keyword
170239
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.